Stocks Health care BMRN
NASDAQ · Health careBiomarin Pharmaceutical Inc (BMRN)
Biomarin Pharmaceutical Inc brought in $3.4B of revenue over the twelve months to June 30, 2026, up 11.2% from a year earlier. Net income was $73M, a net margin of 2.1%. Operating cash flow minus capital spending left $725M of free cash flow in fiscal 2025. At June 30, 2026 it held $874M in cash against $4.2B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Biomarin Pharmaceutical Inc does
Biomarin Pharmaceutical Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BMRN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3.2B | $348.9M | $1.80 | $725M |
| 2024 | $2.9B | $426.9M | $2.21 | $487.4M |
| 2023 | $2.4B | $167.6M | $0.87 | $62.6M |
| 2022 | $2.1B | $141.6M | $0.75 | $54.9M |
| 2021 | $1.8B | -$64.1M | -$0.35 | $209M |
| 2020 | $1.9B | $854M | $4.50 | -$28.9M |
Latest SEC filings
What Biomarin Pharmaceutical Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 15, 2026Other event 8-K
- September 14, 2026
- September 1, 2026Other event 8-K
- August 31, 2026
- August 18, 2026
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- July 13, 2026Other event 8-K/A
- June 4, 2026
Questions about BMRN
What does Biomarin Pharmaceutical Inc do?
Biomarin Pharmaceutical Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BMRN.
Is Biomarin Pharmaceutical Inc profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $73M on revenue of $3.4B, a net margin of 2.1%.
How much revenue does Biomarin Pharmaceutical Inc make?
Over the twelve months to June 30, 2026 Biomarin Pharmaceutical Inc reported revenue of $3.4B. That is 11.2% more than a year earlier.
When did Biomarin Pharmaceutical Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 15, 2026.
Similar companies
Follow BMRN
Get an email when Biomarin Pharmaceutical Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow BMRN: get an email when it filesWhere the numbers come from
Financial figures are the values Biomarin Pharmaceutical Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.